Study of 3 drugs for young AML patients with genetic changes
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your leukemia has a specific genetic change (like KMT2A or NPM1).
- Your leukemia is either not responding to treatment or has come back.
- You are between 1 and 30 years old.
- Your kidneys, liver, and heart are working well.
- You do not have an uncontrolled infection.
- You must be taking certain antifungal medication (posaconazole or voriconazole) before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This trial tests a new drug combination (ziftomenib, venetoclax, and azacitidine) in children and young adults with acute leukemia that has come back or not responded to treatment. It may help if your child's leukemia has certain genetic changes (like KMT2A, NPM1, or NUP98).
This study tests a new combination of three drugs for people with a specific type of acute myeloid leukemia (AML) that has not been treated yet. The drugs target the genetic change (KMT2A) to try to kill the leukemia cells.
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Hear when a new Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.